Projects / Programmes source: ARIS

Biological characteristics of head and neck cancer and the results of treatment

Research activity

Code Science Field Subfield
3.04.00  Medical sciences  Oncology   

Code Science Field
B007  Biomedical sciences  Medicine (human and vertebrates) 
B200  Biomedical sciences  Cytology, oncology, cancerology 
Head and neck carcinoma, postoperative irradiation, Mitomycin C, Bleomycin, tumor biology
Evaluation (rules)
source: COBISS
Researchers (9)
no. Code Name and surname Research area Role Period No. of publicationsNo. of publications
1.  00702  PhD Marjan Budihna  Oncology  Researcher  1997 - 1999  125 
2.  16048  PhD Igor Fajdiga  Oncology  Researcher  1997 - 1999  113 
3.  05315  Ladislava Furlan  Oncology  Researcher  1997 - 1999  20 
4.  17694  Brigita Kušar    Researcher  1997 - 1999 
5.  09762  PhD Hotimir Lešničar  Oncology  Researcher  1997 - 1999  125 
6.  02130  PhD Alojz Šmid  Oncology  Head  1998 - 1999  215 
7.  05316  PhD Erika Šoba-Podobnik  Oncology  Researcher  1999  52 
8.  11747  PhD Branko Zakotnik  Oncology  Researcher  1997 - 1999  425 
9.  02132  PhD Miha Žargi  Oncology  Researcher  1997 - 1999  392 
Organisations (2)
no. Code Research organisation City Registration number No. of publicationsNo. of publications
1.  0302  Institute of Oncology Ljubljana  Ljubljana  5055733000  15,790 
2.  0312  University Medical Centre Ljubljana  Ljubljana  5057272000  77,959 
Our prospective randomized study is aimed to compare two postoperative treatment regimens in patients who present with greater probability of recurrence due to the presence of unfavorable prognostic factors. The patients were randomized either into a group receiving postoperative irradiation alone (standard approach), or into a group treated by irradiation as well as chemotherapy (Mitomycin 15 mg/m2 after received 9-10 Gy radiation dose, and Belomycin 5 mg twice weekly). The proposed combination of postoperative therapy is expected to reduce the number of locoregional recurrences, and possibly improve the survival. It is further presumed that Bleomycin as a radiosensitizer of oxygenated cells should improve the effectivenes of postoperative radiotherapy, while an addition of Mitomycin C would enhance the therapeutic effect exerted on the residual hypoxic tumor cell population. The study will further investigate a possible correlation between certain tumor factors and prognosis of the disease. The randomization of patients will be completed in three years. By the end of the third year, it is expected that we should be able to draw some preliminary conclusions, while the final results will only be available two years after completed study.
Views history